» Articles » PMID: 35763697

Evaluating DNA Recovery Efficiency Following Bisulphite Modification from Plasma Samples Submitted for Cell-free DNA Methylation Analysis

Overview
Journal Epigenetics
Specialty Genetics
Date 2022 Jun 28
PMID 35763697
Authors
Affiliations
Soon will be listed here.
Abstract

The detection of methylated templates in cell-free DNA (cfDNA) is increasingly recognized as a valuable, non-invasive tool for diagnosis, monitoring and prognostication in a range of medical contexts. The importance of controlling pre-analytical conditions in laboratory workflows prior to cfDNA quantification is well-established. Significant variations in the recovery of DNA following processes such as cfDNA extraction and sodium bisulphite modification may confound downstream analysis, particularly when accurate quantification of templates is required. Given the wealth of potential applications for this emerging molecular technology, attention has turned to the requirement to recognize and minimize pre-analytical variables prior to cfDNA methylation analysis. We recently described the development of an approach using an exogenous DNA construct to evaluate the recovery efficiency of cfDNA following the extraction and bisulphite modification steps (CEREBIS). Here, we report our experience in the practical application of this technique in 107 consecutive patient plasma samples submitted for quantitative cfDNA methylation analysis. The mean recovery of cfDNA (as estimated using cerebis), following extraction and bisulphite modification, was 37% ± 7%. Nine (8.4%) of the 107 samples were found to be outside of control limits, where the recovery of cerebis indicated significant differences in the efficiency of the pre-analytical processing of these samples. Recognition of these out-of-control samples precluded subsequent molecular analysis. Implementation of data-driven quality control measures, such as the one described, has the potential to improve the quality of liquid biopsy methylation analysis, interpretation and reporting.

Citing Articles

An overview of DNA methylation markers for early detection of gastric cancer: current status, challenges, and prospects.

Xue Y, Huang C, Pei B, Wang Z, Dai Y Front Genet. 2023; 14:1234645.

PMID: 37560387 PMC: 10407555. DOI: 10.3389/fgene.2023.1234645.


Graft-Derived Cell-Free DNA Quantification following Liver Transplantation Using Tissue-Specific DNA Methylation and Donor-Specific Genotyping Techniques: An Orthogonal Comparison Study.

Cox D, McClure T, Zhang F, Wong B, Testro A, Goh S Epigenomes. 2023; 7(2).

PMID: 37367181 PMC: 10296814. DOI: 10.3390/epigenomes7020011.

References
1.
Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

2.
Van Paemel R, De Koker A, Caggiano C, Morlion A, Mestdagh P, De Wilde B . Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. Epigenetics. 2020; 16(7):797-807. PMC: 8216177. DOI: 10.1080/15592294.2020.1827714. View

3.
Cox D, Low N, Goh S, Lee E, Vago A, Jackett L . Low Levels of Hepatocyte-Specific Methylation in Cell-Free DNA Are a Strong Negative Predictor for Acute T Cell-Mediated Rejection Requiring Treatment Following Liver Transplantation. Liver Transpl. 2021; 28(6):1024-1038. DOI: 10.1002/lt.26388. View

4.
Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J . Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer. 2018; 118(9):1217-1228. PMC: 5943265. DOI: 10.1038/s41416-018-0035-8. View

5.
Huggett J . The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. Clin Chem. 2020; 66(8):1012-1029. DOI: 10.1093/clinchem/hvaa125. View